Does Fosamax Cause Osteonecrosis of the Jaw? A Review of Clinical Evidence and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Inquiry

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions of medication side effects typically remain at a population level, emphasizing statistical risks and benefits without delving into individual exposure pathways. This heritage provides a necessary baseline for evaluating therapeutic interventions, yet it often stops short of examining how specific patient histories or environmental factors may modify risk profiles. Transitioning from this general framework to a more focused concern, the question of Fosamax exposure and its potential association with osteonecrosis of the jaw represents a shift toward occupational and clinical exposure considerations. While the original health information context addresses broad medication safety, the pivot here involves recognizing that certain patient populations—particularly those with prolonged or high-dose bisphosphonate use—may face distinct risk scenarios. This does not imply causation but rather highlights the need to examine exposure duration, cumulative dosage, and concurrent health factors as variables that could influence outcomes. The bridge concept thus moves from general awareness to a targeted inquiry: how does sustained Fosamax exposure, within specific clinical or occupational settings, relate to the observed incidence of jaw complications? This reframing preserves the neutral tone of academic inquiry while narrowing the lens from universal health guidance to a precise exposure-risk consideration.

Fosamax and Osteonecrosis of the Jaw: An Overview of the Association

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The question of whether Fosamax causes ONJ requires careful examination of clinical evidence, mechanistic pathways, and risk considerations. Clinical evidence from FDA-approved labeling indicates that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling explicitly states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This association is documented in the warnings and precautions section of the drug's prescribing information, indicating a recognized risk. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms related to ONJ were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that the incidence in controlled trials was not statistically elevated. This discrepancy highlights the complexity of establishing direct causation, as ONJ can occur spontaneously and is influenced by multiple factors.

Mechanistic Pathways and Risk Factors for ONJ in Fosamax Users

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits bone resorption by osteoclasts. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone has unique properties, including high bone turnover and susceptibility to infection and trauma, which may make it particularly vulnerable to bisphosphonate-induced suppression of bone remodeling. This suppression can impair the repair of microdamage and reduce blood supply, potentially leading to necrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), suggesting a cumulative effect.

Temporal Relationship and Causation Considerations

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some individuals, as the temporal association and response to dechallenge and rechallenge are consistent with drug-induced effects. However, the variability in onset and the influence of other risk factors complicate individual causation assessments. Risk considerations for affected patients include the adequacy of warnings. The FDA-approved labeling includes a specific section on osteonecrosis of the jaw, detailing the association and risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This recommendation indicates that the labeling provides guidance for risk mitigation. However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This limitation underscores the need for individualized benefit-risk assessment.

Summary of Evidence and Clinical Implications

Causation-related considerations for affected patients involve evaluating the presence of other risk factors, the temporal relationship, and the response to drug discontinuation. While the evidence supports an association between Fosamax and ONJ, particularly in patients with additional risk factors, establishing causation in a specific case requires careful clinical evaluation. The labeling notes that ONJ can occur spontaneously, and the incidence in clinical trials was similar to placebo, suggesting that Fosamax may not be the sole cause but can contribute in susceptible individuals. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, as documented in FDA-approved labeling and supported by mechanistic understanding of bisphosphonate effects on jawbone. The risk is influenced by duration of use, dental procedures, and other patient factors. Adequate warnings are provided in the prescribing information, and risk mitigation strategies, such as dental evaluation and consideration of drug discontinuation before invasive procedures, are recommended. For affected patients, a thorough assessment of individual risk factors and temporal patterns is necessary to evaluate causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ) in FDA-approved labeling. Clinical trials showed similar incidence in Fosamax and placebo groups, but postmarketing reports and mechanistic studies support an increased risk, especially with prolonged use and additional risk factors such as dental procedures or cancer therapy.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ occur?

The time to onset of ONJ symptoms can range from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients improve after stopping the drug, but some may experience recurrence if rechallenged.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.